Ventas, Inc. VTR · NYSE
$84.47 -1.62% (-$1.39)
Summary
57 / 100 · Bulios Score
What speaks for it
- Revenue grew by 12% a year over the last 3 years.
- Out of every 100 USD of revenue, 25 USD is left as free cash.
- Analysts expect revenue to grow by 19% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- Out of every 100 USD of revenue, only 4.1 USD is left as net profit.
- Operating profit covers the interest on its debt only 1.3 times.
- It earns only 3.4 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 162.7 USD for 1 USD of yearly profit. Over the last five years it was 282.5 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 9.0% a year over 5 years. Over the last 3 years it grew by 12% a year. For the next fiscal year analysts expect revenue to grow by 19%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 103 USD
- Sales and administration -16 USD
- Taxes and other 8.8 USD
- Net profit 4.1 USD
Net profit, industry median (REIT - Healthcare Facilities) 11 USD
Out of every 100 USD of revenue, 4.1 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 8.5 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 2.42%
- Paid out of profit
- 393%
- Raised in a row
- 1 year
You receive $2.04 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 18
- Hold 12
- Sell 2
Today's price within the analysts' price targets
The average target of $99.93 is 18% above today's price. 56% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Senior Living Operations 74%
- Outpatient Medical And Research Portfolio 16%
- Triple Net Leased Properties 10%
By region
- UNITED STATES 89%
- CANADA 9.5%
- UNITED KINGDOM 1.2%
Senior Living Operations brings in 74% of revenue.
Segments in detail